Charles M. Rudin

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Charles M. Rudin

Oct 12, 2024, 22:16 | Insight

Triparna Sen: CD38-mediated immunosuppression as a potential mechanism of tumor cell escape from PDL1 inhibition in SCLC

Triparna Sen, Associate Professor, Icahn School of Medicine at Mount Sinai, shared a post on…

Jul 26, 2024, 00:16 | Insight

Impact of the intratumoral microbiome of NSCLC on outcomes with immunotherapy

Stephen Liu shared on X: "Impressive work on impact of the intratumoral microbiome of NSCLC…

Jul 25, 2024, 00:32 | Blog

Jarushka Naidoo: Can intratumor eschericia improve OS from ICIs in NSCLC

Jarushka Naidoo shared a post on X: ''Can intratumor eschericia (E) bring immune cells to…

Apr 26, 2024, 20:26 | Insight

New Paper Alert! Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial

Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial Authors:…

All: 4 Posts: 1 - 100